维普中文期刊产品整合服务
9篇 您的检索式:作者名="Odin L"
    题名 作者 年代 出处 被引量
1Bcl-2- dependent oxidation of pyruvate dehydrogenase-E2,a primary biliary cirrhosis autoantigen,during apoptosis显示文摘Odin JA Huebert RC Casciola-Rosen L 2001J Clin Invest2001,108,2:1
2Canarypox virus-mediated interleukin-12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity显示文摘PUISIEUX I ODIN L POUJOL D 1998Hum Gene Ther1998,9,:1
3Vaccination as a triggering event for autoimmune hepatitis显示文摘Perumalswami P Peng L Odin JA 2009Semin Liver Disease2009,29,3:1
4Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs.Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch 2017World Journal of Virology2017,6,4:1
5Canarypox virus-mediated interleukin-12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity显示文摘Puisieux I Odin L Poujol D Moingeon P Tartaglia J Cox W 1998Hum Gene Ther1998,9,17:1
6Canarypox virus-mediated interleukin-12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunoity显示文摘Puisieux I Odin L Poujol D 1998Hum Gene Ther1998,9,:1
7Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen,during apoptosis 显示文摘Odin J A Huebert R C Casciola-Rogen L 2001J Clin Invest2001,108,2:1
8Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study显示文摘C Warren Olanow Karl Kieburtz Per Odin Alberto J Espay David G Standaert Hubert H Fernandez Arvydas Vanagunas Ahmed A Othman Katherine L Widnell Weining Z Robieson Yili Pritchett Krai Chatamra Janet Benesh Robert A Lenz Angelo Antonini 2013Lancet Neurology2013,,:1
9Canarypox virus-mediated in- terleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity 显示文摘Puisieux I Odin L Poujol D 1998Hum Gene Ther1998,9,17:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费